Generic Lovenox In EU Will Require Clinical Data, Shrinking Sandoz’s Opportunity
Executive Summary
An EU guidance issued earlier this year requiring clinical trials for generic copies of low molecular weight heparins may just have shot the European market opportunity for Momenta and its partner Sandoz, according to Momenta's CFO Rick Shea
You may also be interested in...
FDA Approves Momenta/Sandoz' Lovenox Generic Without Need For Clinical Studies
FDA approval of Momenta and Sandoz' generic version of Sanofi-Aventis' Lovenox (enoxaparin) suggests the agency is willing to find a way around requiring clinical efficacy and safety data for future biosimilar approvals
FDA Approves Momenta/Sandoz' Lovenox Generic Without Need For Clinical Studies
FDA approval of Momenta and Sandoz' generic version of Sanofi-Aventis' Lovenox (enoxaparin) suggests the agency is willing to find a way around requiring clinical efficacy and safety data for future biosimilar approvals
FDA Approves Momenta/Sandoz' Lovenox Generic Without Need For Clinical Studies
Agency's five criteria for determining "sameness" of generic enoxaparin to Sanofi-Aventis's low molecular weight heparin could serve as guideposts for future biosimilar approvals.